Canda, EbruYazici, HavvaEr, EsraUcar, Sema KalkanOnay, HuseyinSozmen, EserÖzkınay, FerdaCoker, Mahmut2019-10-272019-10-2720182147-94452147-9445https://doi.org/10.4274/jpr.75046https://hdl.handle.net/11454/30602Aim: Niemann-Pick disease (NPD) is a lysosomal storage disease caused by an insufficient activity of acid sphingomyelinase (ASM) resulting in the accumulation of sphingomyelin. Type A is an infantile neurovisceral fatal form characterized by hepatosplenomegaly and rapidly progressive neurological deterioration, while the Type B non-neuronopathic disease presents visceral form and sufferers usually survive into adulthood. Materials and Methods: Here we present clinical and molecular findings for 19 patients with NPO A/B. Results: Nineteen patients with ASM deficiency were enrolled in our study. Nine of them were female and ten patients were male. The median age of the patients was 7.5 years (minimum-maximum: 1-57 years), the median age at diagnosis was 3 years (minimum-maximum: 6 months-56 years). The median length of the follow up period was 4.07 +/- 3.8 years (range: 1 month-14years). Eighteen patients had hepatosplenomegaly, one patient had splenomegaly. Pulmonary involvement was detected in 10 patients. Six patients died during follow up. Conclusion: Patients with Niemann Pick A/B have a high mortality and morbidity rate. There is a need for a safe and effective therapy for patients with NPD A/B to reduce splenomegaly, to improve liver and respiratory function and to reduce the rate of mortality and morbidity.en10.4274/jpr.75046info:eu-repo/semantics/openAccessHepatosplenomegalyinterstitial pulmonary diseasecytopeniaacid sphingomyelinaseArticle512227WOS:000436882600006N/A